Introduction
============

Obstructive sleep apnea (OSA) is characterized by repetitive and partial or total collapse of the upper airway during sleep. This disorder results in decreased or complete cessation of airflow during sleep despite the presence of breathing effort.[@b1-jaa-10-285] OSA is the most common respiratory disorder during sleep and has a significant prevalence in the general population.[@b2-jaa-10-285] In children, the prevalence of OSA is approximately 1.2%--5.7%, with the high peak in preschool and school-aged children.[@b3-jaa-10-285],[@b4-jaa-10-285] Recently, an increasing number of studies have been conducted to study the relationship between OSA and other lower airway diseases especially in asthma in terms of prevalence, pathophysiology, and disease control. Previous studies suggested that asthma and OSA may coexist because they are chronic inflammations of the airways.[@b5-jaa-10-285],[@b6-jaa-10-285] However, until now, the prevalence of OSA in patients with asthma, especially in children with asthma, has not been clearly demonstrated. In a recent systematic review, Sánchez et al[@b7-jaa-10-285] showed that children with asthma had a significant and higher risk of OSA than subjects without OSA and that both diseases shared some similar symptoms (overlap) during sleep, making the diagnosis of each more difficult.

In children with OSA, due to the intermittent hypoxia at night, in the long term they might develop hemodynamic, metabolic, and mental disorders. These consequences are more hazardous with harmful effects on the psychological and physical development and also on the ability of learning and memory performance in children with OSA.[@b8-jaa-10-285],[@b9-jaa-10-285] In asthmatic children with OSA, these symptoms were more severe and usually associated with sleep disturbance, daytime sleepiness, and tiredness.[@b10-jaa-10-285] Furthermore, OSA is also a common comorbidity in asthma and may disturb asthma control, and inversely, the asthma status makes OSA more severe.[@b11-jaa-10-285]

This study was planned to describe: 1) the prevalence of OSA in children with asthma; 2) the clinical and functional characteristics of asthmatic children with OSA; and 3) the suggestive symptoms of asthmatic children for a higher risk of OSA.

Subjects and methods
====================

Subjects
--------

Children diagnosed with asthma who had been presented to the Department of Asthma and Immuno-Allergology of the National Hospital of Pediatrics (Hanoi, Vietnam) from November 2015 to August 2016 were included in the present study after their parents or legal guardians signed an institutional review board-approved consent form.

Inclusion criteria
------------------

All subjects diagnosed with asthma and aged between 6 and 17 years were included in the present study if they were out of acute asthma exacerbation and able to perform spirometry, exhaled nitric oxide (NO) measurement, skin prick test (SPT), and polygraphy (PG) at night. The diagnosis of asthma was based on the criteria recommended by Global Initiative for Asthma (GINA) 2015 for children over 5 years old.[@b12-jaa-10-285] The subjects who had other diseases had been excluded from the present study.

Exclusion criteria
------------------

Study subjects were excluded from the study if they had one of the following features: asthma crisis or severe asthma exacerbations needing systemic corticosteroid therapy (oral or injection) at inclusion, any significant other chronic or acute diseases, facial structure malformation, or enlarged tonsils.

Methods
-------

### Study design

It was a prospective and descriptive study. All study subjects were followed up regularly at the Department of Asthma and Immuno-Allergology. This study was approved by the ethical review board of the National Hospital of Pediatrics (Hanoi, Vietnam).

Depending on asthma severity, the study subjects were treated as recommended by GINA (intermittent asthma: short-acting beta agonist \[SABA\] as needed; mild asthma: low-dose inhaled corticosteroid (ICS) + SABA; moderate asthma: moderate- to high-dose ICS + SABA; severe asthma: moderate- to high-dose ICS + long-acting beta agonist + SABA). The asthma control test (ACT) was used as a self-assessment by the study subjects (≥12 years) or their parents (\<12 years). The level of asthma control was defined as recommended by GINA: controlled, partially controlled, and uncontrolled asthma.[@b12-jaa-10-285]

OSA was diagnosed by PG, and the apnea--hypopnea index (AHI) was used to classify the severity of OSA for children ≤12 years as recommended: normal (non-OSA): AHI ≤ 1/h; mild OSA: 1/h \< AHI ≤ 5/h; moderate OSA: 5/h \< AHI ≤ 10/h; and severe OSA: AHI \> 10/h.[@b13-jaa-10-285] The severity of OSA for children \>12 years was defined similarly with adult classification: normal (non-OSA): AHI ≤ 5/h; mild OSA: 5/h \< AHI ≤ 15/h; moderate OSA: 15/h \< AHI ≤ 30/h; and severe OSA: AHI \> 30/h. PG was realized with ApneaLink (ResMed; San Diego, CA, USA) at home by trained physicians who were the members of the Study Board.

The SPT was done using Stallergenes Kit (Stallergenes; London, UK), and the negative control was 0.9% saline solution and the positive control was 1 mg/mL of histamine. Six respiratory allergens including *Dermatophagoides pteronyssinus* (Dp), *Dermatophagoides farinae* (Df), *Blomia tropicalis* (Blo), and hairs and epidermis of dogs, cats, and cockroaches were tested. The SPT was considered positive when the wheal size exceeded the negative control by 3 mm.

Lung function testing (spirometry) was done by Koko (nSpire Health, Inc., Longmont, CO, USA). The reversibility of forced expiratory volume in 1 s (FEV~1~) was evaluated after using 200 μg of salbutamol for 15 min. The test was positive when there was an increase in FEV~1~ ≥12% and \>200 mL. Measuring exhaled NO concentration was done by Hypair FeNO+ Device (Medisoft; Sorinnes, Belgium) with expiratory air flow of 50, 100, 150, 350 mL/s. Fractional exhaled nitric oxide (FENO) levels were classified as recommended by the American Thoracic Society/European Respiratory Society (ATS/ERS) for children (\<20 ppb: normal; 20--35 ppb: increased; and \>35 ppb: highly increased).[@b14-jaa-10-285] The level of alveolar concentration of exhaled NO (C~A~NO) \< 5 ppb was defined as normal.[@b15-jaa-10-285]

### Data collection

All data on medical and family history, clinical characteristics, measures of spirometry, exhaled NO, SPT and PG parameters of the study subjects were collected for statistical analyses.

### Statistical analyses

SPSS 22.0 software (IBM Corporation, Armonk, NY, USA) was used to analyze these collected data. Continuous variables were presented as mean ± standard deviation (SD). Normal distribution was tested using the Skewness--Kurtosis technique. The pairwise comparison was performed using the Kruskal--Wallis test. The regression analysis was used to measure the correlation between AHI and continuous variables, with the correlation coefficient *R* of Pearson for normal distribution variables and of Spearman for non-normal distribution variables. The Mann--Whitney *U*-test was used to evaluate the correlation between AHI and asthma severity.

Results
=======

Clinical and paraclinical characteristics of the study subjects
---------------------------------------------------------------

Eighty-five children with asthma have been included in the present study. The mean age was 9.5 ± 2.1 years (6--12 years) with 72.8% of male and 27.2% of female children ([Table 1A](#t1A-jaa-10-285){ref-type="table"}). Approximately 78.8% of the study subjects had a history of atopic diseases, predominantly with allergic rhinitis (76.5%); 7.1% of the study subjects were diagnosed with gastroesophageal reflux (GER) and 44.7% with second hand smokers ([Table 1A](#t1A-jaa-10-285){ref-type="table"}). Approximately 52.5% of the study subjects had mild asthma vs 18.8% intermittent asthma and 28.3% moderate asthma. Among them, only 29.4% subjects had been treated regularly and 18.8% had totally controlled asthma.

The majority of asthmatic children were allergic to house dust mites with 76.5% for Dp, 65.9% for Df, and 41.2% for Blomia ([Table 1B](#t1B-jaa-10-285){ref-type="table"}). The mean levels of IgE and the percentage of eosinophil in the study subjects were higher than normal values. The mean FEV~1~ and peak expiratory flow (PEF) in the study subjects were mildly lower than normal value ([Table 1B](#t1B-jaa-10-285){ref-type="table"}). Forty-four (51.4%) asthmatic children were positive on the reversibility test. The nasal and alveolar concentrations of NO were higher than normal values (1501 ± 907 ppb and 6.3 ± 5.9 ppb, respectively; [Table 1B](#t1B-jaa-10-285){ref-type="table"}).

There were 56 (65.9%) asthmatic children who had OSA vs 29 (34.1%) children with asthma who did not have OSA. Among the asthmatic children with OSA (56 patients), there were 31 (55.4%) patients with mild OSA, 19 (33.9%) with moderate OSA, and 6 (10.7%) with severe OSA (AHI ≥10/h). The average AHI index was 3.4 ± 3.5/h (0--13/h). The mean SpO~2~ was 84.6% ± 20.8% and the nadir SpO~2~ was 79.6% ± 8.2%. The oxygen desaturation index (ODI) was 4.3 ± 3.1/h.

Characteristics of the study subjects classified by OSA
-------------------------------------------------------

There was no significant difference in the anthropometric characteristics between asthmatic subjects with and without OSA ([Table 2](#t2-jaa-10-285){ref-type="table"}). There were also no significant differences in asthma treatment, asthma severity, and asthma control between the two groups (*P* \> 0.05). The results showed that the prevalence of allergic rhinitis in asthma subjects with OSA was significantly higher than that in asthma subjects without OSA (69.6% vs 46.2%; *P* = 0.006; [Table 2](#t2-jaa-10-285){ref-type="table"}). The levels of eosinophil, nasal FENO, SpO~2~, and nadir SpO~2~ were not significantly different between the two groups ([Table 2](#t2-jaa-10-285){ref-type="table"}). However, the levels of FEV~1~, bronchial FENO, and C~A~NO in asthma subjects with OSA were significantly higher than that in subjects without OSA ([Table 2](#t2-jaa-10-285){ref-type="table"}).

Characteristics of nocturnal and day-time symptoms
--------------------------------------------------

The results showed that the percentages of asthmatic children with OSA who had snoring, disturbed sleep, and complaints with nocturnal sweats were significantly higher than asthmatic children without OSA (48.2% vs 17.2%, 71.4% vs 27.5%, and 55.1% vs 31.0%; *P* = 0.002, *P* \< 0.001, and *P* = 0.011, respectively; [Table 3](#t3-jaa-10-285){ref-type="table"}). For daytime symptoms, the napping was presented only in asthmatic children with OSA while daytime sleepiness was presented predominantly in asthmatic children without OSA (23.2% vs 0.0% and 37.9% vs 16.0%; *P* = 0.002 and *P* = 0.012, respectively; [Table 3](#t3-jaa-10-285){ref-type="table"}).

Frequency of distribution of OSA and asthma severity
----------------------------------------------------

The prevalence of mild OSA was significantly lower in children with moderate asthma in comparison with intermittent and mild asthma (23.5% vs 63.6% and 71.4%; *P* = 0.016 and *P* = 0.0008, respectively; [Figure 1A](#f1-jaa-10-285){ref-type="fig"}). There were no significant differences in the prevalence of moderate OSA in children with intermittent, mild, and moderate asthma (36.4% vs 25.0% vs 47.1%; *P* = 0.238, *P* = 0.288, and *P* = 0.064, respectively). The prevalence of severe OSA in children with moderate asthma was significantly higher than in those with intermittent and mild asthma (29.4% vs 0.0% and 3.6%; *P* = 0.023 and *P* = 0.006, respectively; [Figure 1A](#f1-jaa-10-285){ref-type="fig"}).

Similarly, the prevalence of mild asthma in children with severe OSA was significantly lower than that in asthmatic children without OSA and with mild OSA (16.7% vs 58.6% and 64.5%; *P* = 0.030 and *P* = 0.015, respectively; [Figure 1B](#f1-jaa-10-285){ref-type="fig"}). The prevalence of moderate asthma in children with severe OSA was significantly higher than that in asthma children without and with mild to moderate OSA (83.3% vs 24.2%, 12.9%, and 42.1%; *P* = 0.020, *P* = 0.0002, and *P* = 0.039, respectively; [Figure 1B](#f1-jaa-10-285){ref-type="fig"}). However, there were no significant differences in the prevalence of intermittent asthma in children without OSA and with mild, moderate, and severe OSA (17.2%, 22.6%, 21.1%, and 0.0%; *P* = 0.302, *P* = 0.370, *P* = 0.135, *P* = 0.449, *P* = 0.09, and *P* = 0.110, respectively).

Relative measure (odds ratio, OR) of OSA risk in the study subjects
-------------------------------------------------------------------

The presence of allergic rhinitis and snoring was associated significantly with high probability for the presence of OSA (OR = 6.8, CI 95%: 2.2--20.7, *P* = 0.001; OR = 4.9, 95% CI: 1.8--13.3, *P* = 0.002, respectively; [Table 4](#t4-jaa-10-285){ref-type="table"}; [Figure 2](#f2-jaa-10-285){ref-type="fig"}). However, the presence of disturbed sleep, nocturnal sweats, and FEV~1~ \<80% of predicted value was not associated with a significant presence of OSA in subjects with asthma ([Table 4](#t4-jaa-10-285){ref-type="table"} and [Figure 2](#f2-jaa-10-285){ref-type="fig"}). The presence of increased exhaled NO (bronchial and alveolar exhaled NO) was not a predictive factor for the presence of OSA in the study subjects.

Discussion
==========

The results of the present study showed that 1) the prevalence of OSA in children with asthma was predominantly in moderate asthma; 2) the prevalence of allergic rhinitis and sleep-related disorders in asthma subjects with OSA was significantly higher than that in subjects without OSA; 3) the level of exhaled NO (FENO and C~A~NO) in asthma subjects with OSA was significantly higher than subjects without OSA; and 4) the presence of allergic rhinitis, dyspnea, and snoring during sleep in asthma subjects was significantly associated with a higher probability of the presence of OSA.

In the present study, 65.9% of the asthmatic patients having OSA were diagnosed by PG (AHI ≥1/h; [Table 1B](#t1B-jaa-10-285){ref-type="table"}). However, if study subjects with mild OSA should be excluded from the analysis or the cutoff of AHI \> 5 for diagnosis of OSA, the percentage of children with asthma having OSA will be significantly lower (36.5%; data not shown). Especially, the prevalence of severe OSA in subjects with moderate asthma was significantly higher than intermittent and mild asthma subjects and inversely the percentage of patients with moderate asthma was significantly higher in severe OSA ([Tables 1A](#t1A-jaa-10-285){ref-type="table"} and [1B](#t1B-jaa-10-285){ref-type="table"}). In addition, AHI was significantly higher in patients with moderate asthma and in uncontrolled asthma (data not shown). However, there were no significant differences between asthma subjects with OSA and without OSA for the distribution frequency of asthma severity, treatment adherence, and asthma control ([Table 2](#t2-jaa-10-285){ref-type="table"}). Previous studies also demonstrated the correlation between asthma severity and AHI.[@b7-jaa-10-285],[@b16-jaa-10-285] In adults, Julien et al[@b16-jaa-10-285] showed that the prevalence of OSA, diagnosed by AHI ≥ 15/h, was 88% in the severe asthma group and 58% in the moderate asthma group.[@b16-jaa-10-285] In children, based on the result of a recent systematic review, Sánchez et al[@b7-jaa-10-285] concluded that children with asthma were more likely to develop habitual snoring and OSA, and children with sleep-disordered breathing (SDB) were more likely to develop asthma. Moreover, the authors found out that asthma was associated with more severe OSA, and the presence of SDB was associated with severe asthma.

The present study showed that 78.8% of the study subjects had an atopic disease with 76.5% of allergic rhinitis, diagnosed by clinical symptoms and nasal FENO measurement ([Tables 1A](#t1A-jaa-10-285){ref-type="table"} and [1B](#t1B-jaa-10-285){ref-type="table"}). The high prevalence of allergic rhinitis in asthma subjects in the present study was similar to another previous study.[@b17-jaa-10-285] Braido et al[@b18-jaa-10-285] found that approximately 80% of patients with asthma had allergic rhinitis as a comorbidity and increased risk of OSA. As with our previous study,[@b17-jaa-10-285] in the present study, there were \>80% of asthma patients with allergic rhinitis having nasal congestion. It has been suggested that nasal congestion, a prominent and bothersome symptom of allergic rhinitis, is linked to SDB, including snoring and sleep apnea.[@b19-jaa-10-285],[@b20-jaa-10-285] The role of nasal congestion in increasing the AHI has been confirmed by previous studies in sleep-related problems with the nasal occlusion model.[@b21-jaa-10-285],[@b22-jaa-10-285] However, until now, the exact mechanism for the link between allergic rhinitis and OSA has not been clearly identified.

The results of our study show that the percentage of asthma subjects with OSA having snoring, disturbed sleep, apnea during sleep, nocturnal sweats, and day-time sleepiness was significantly higher than that in asthma subjects without OSA ([Table 3](#t3-jaa-10-285){ref-type="table"}). These symptoms were discovered by parents at night during sleep and at schools during class. The sleepiness during class time might reflect significantly on the day-time consequence of bad sleep quality. In addition, among these symptoms, there was only the snoring and dyspnea during sleep and a high probability for the presence of OSA in asthma subjects ([Table 4](#t4-jaa-10-285){ref-type="table"}). This result might be very interesting in regard to the use of snoring and dyspnea during sleep as suggestive symptoms of OSA in patients with asthma. Inversely, the results of previous studies showed that subjects with habitual snoring and OSA had a statistically significant predictor of asthma.[@b23-jaa-10-285]--[@b25-jaa-10-285] However, the bidirectional correlation between asthma and OSA is still controversial.[@b26-jaa-10-285] OSA may induce asthma exacerbation via different mechanisms such as by altering oropharyngeal reflex or increasing cholinergic tone.[@b27-jaa-10-285] However, asthma may induce disrupted sleep and increased AHI in snorers.[@b28-jaa-10-285] In addition, in asthmatic children with OSA, uncontrolled asthma might accentuate upper and lower airway inflammation via the intermittent nocturnal hypoxemia.[@b28-jaa-10-285],[@b29-jaa-10-285] The present study showed that enuresis was not a specific symptom of OSA in children with asthma because it was present predominantly in children without OSA ([Table 3](#t3-jaa-10-285){ref-type="table"}).

The present study also showed that asthma patients with OSA had some paraclinical parameters significantly different from asthma patients without OSA ([Table 1B](#t1B-jaa-10-285){ref-type="table"}). Asthma subjects with OSA had a lower FEV~1~ and higher exhaled NO levels (bronchial FENO and C~A~NO) than asthma subjects without OSA. The low FEV~1~ in asthma subjects (moderate asthma) with OSA was similar to the high distribution prevalence of moderate to severe OSA in these patients ([Figure 1A and B](#f1-jaa-10-285){ref-type="fig"}). This result suggests that there was a link between airway obstruction in asthma and OSA severity. In the present study, the spirometry parameters had been used mainly to evaluate the severity of airflow limitation and its reversibility as recommended by GINA, and due to the study population was children, the other lung testing such as diffusing capacity of lung for carbon monoxide (DLCO) had not been done for additional parameter analysis.

The results of our previous study on subjects with OSA and without asthma demonstrated that the level of C~A~NO was significantly increased at wake up, suggesting that the measurement of C~A~NO at wake up was useful to predict the risk of OSA in subjects with suggestive symptoms.[@b15-jaa-10-285] Therefore, C~A~NO may be used as a surrogate marker for subjects with OSA without other airway diseases. However, the role of C~A~NO in asthma subjects with OSA has not been demonstrated. In the present study, although the level of C~A~NO was significantly higher in asthma subjects with OSA than that in asthma subjects without OSA, there was no significant link between increased C~A~NO and OSA risk ([Table 4](#t4-jaa-10-285){ref-type="table"} and [Figure 2](#f2-jaa-10-285){ref-type="fig"}). Hence, we suggest that the high level of C~A~NO in asthma patients with OSA might be due to airway inflammation rather than oxidative stress.

The results of measuring the OR of significant clinical and functional features in asthma subjects with OSA in the present study showed that the presence of allergic rhinitis and snoring was associated with a higher probability for the presence of OSA ([Table 4](#t4-jaa-10-285){ref-type="table"} and [Figure 2](#f2-jaa-10-285){ref-type="fig"}). This result suggests that the presence of allergic rhinitis, a common comorbidity in asthma patients, is a risk for OSA, especially when it is associated with snoring at night. The presence of allergic rhinitis and snoring in asthma subjects might be considered as a relevant marker of OSA and also a main criterion for investigating sleep-disorder breathing with PG or polysomnography. Interestingly, the coexistence of asthma and OSA might be a specific clinical phenotype for the management and the control of asthma in children. More studies are necessary to study the role of treatment option for asthmatic children with OSA; it should be based on the presence or absence of allergic rhinitis as a treatable comorbidity and the efficacy of some recommended drugs such as leukotriene antagonists.

Conclusion
==========

OSA is a common comorbidity in children with asthma. It was dominant in subjects with moderate and uncontrolled asthma. The presence of allergic rhinitis, snoring, and dyspnea during sleep in asthmatic children is associated with a higher risk of OSA. Hence, PG or polysomnography should be performed on asthmatic children with suggestive symptoms of OSA.
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###### 

Clinical characteristics of the study subjects

  Parameters (N = 85)                    Mean ± SD, N (%)
  -------------------------------------- ------------------
  Age, years                             9.5 ± 2.1
  Male (female), %                       72.8 (28.2)
  Height, cm                             134.5 ± 12.5
  Weight, kg                             31.9 ± 8.2
  BMI, kg/m^2^                           17.4 ± 2.8
  Atopic diseases, N (%)                 67 (78.8)
   Eczema, %                             21.2
   Allergic rhinitis, %                  76.5
   Allergic conjunctivitis, %            35.3
   Urticaria, %                          17.6
   Drug allergy, %                       5.9
   Food allergy, %                       16.5
  Familial history with allergy, N (%)   55 (64.7)
  GER, N (%)                             6 (7.1)
  Second hand smoker, N (%)              38 (44.7)
  Asthma management, N (%)               
   Never treated                         26 (30.6)
   Occasionally treated                  34 (40.0)
   Correctly treated                     25 (29.4)
  Asthma severity, N (%)                 
  Intermittent                           16/85 (18.8)
  Mild                                   45/85 (52.9)
  Moderate                               24/85 (28.3)
  Severe                                 0/85 (0.0)
  Asthma control, N (%)                  
  Controlled                             16/85 (18.8)
  Partial controlled                     23/85 (27.1)
  Uncontrolled                           46/85 (54.1)
  ACT, score                             20.3 ± 3.7

**Abbreviations:** ACT, asthma control test; BMI, body mass index; GER, gastroesophageal reflux.

###### 

Paraclinical characteristics of the study subjects

  Parameters (N = 85)                                       Mean ± SD, N (%)
  --------------------------------------------------------- -------------------
  SPT, N (%)                                                
   Dp                                                       65/85 (76.5)
   Df                                                       56/85 (65.9)
   Blo                                                      35/85 (41.2)
   Cockroaches                                              16/85 (18.8)
   Dog hairs                                                12/85 (14.1)
   Cat hairs                                                24/85 (28.2)
  Blood tests                                               
   Eosinophil, %                                            6.3 ± 4.9
   CRP, mg/L                                                3.1 ± 4.7
   IgE, UI/L                                                946.4 ± 984.6
  Spirometry[a](#tfn2-jaa-10-285){ref-type="table-fn"}, %   
   FEV~1~                                                   89.4 ± 15.9
   FVC                                                      95.5 ±15.2
   FEV~1~/FVC                                               93.8 ± 7.9
   PEF                                                      71.6 ± 14.7
  Reversibility, N (%)                                      
   Positive                                                 44 (51.8)
   Negative                                                 41 (48.2)
  Exhaled NO, ppb                                           
   Bronchial FENO                                           19 ± 14
   Nasal FENO                                               1501 ± 907
   C~A~NO                                                   6.3 ± 5.9
  Polygraphy                                                
   AHI (min, max)                                           3.4 ± 3.5 (0--13)
    ≤1/h (normal), N (%)                                    29 (34.1)
    \>1/h (OSA), N (%)                                      56 (65.9)
    1 \< AHI ≤ 5/h (mild), %                                55.4
    5 \< AHI ≤ 10/h (moderate), %                           33.9
    \>10/h (severe), %                                      10.7
   SpO~2~, %                                                84.6 ± 20.8
   Nadir SpO~2~, %                                          79.6 ± 8.2

**Notes:**

Post-reversibility testing.

**Abbreviations:** AHI, apnea--hypopnea index; Blo, *Blomia tropicalis*; CANO, alveolar concentration of nitric oxide; CRP, C reactive protein; Df, *Dermatophagoides farinae*; Dp, *Dermatophagoides pteronyssinus*; FENO, fractional exhaled nitric oxide; FEV~1~, forced expiratory flow in 1 second; FVC, forced vital capacity; IgE, immunoglobulin E; max, maximum; min, minimum; NO, nitric oxide; OSA, obstructive sleep apnea; PEF, peak expiratory flow; SPT, skin prick test.

###### 

Clinical and paraclinical characteristics of the study subjects classified by OSA

  Parameters                 Asthma + OSA (−), N = 29   Asthma + OSA (+), N = 56   *P*
  -------------------------- -------------------------- -------------------------- -------
  Age, years                 9.7 ± 2.1                  9.4 ± 2.1                  0.40
  Male (female), ratio       22/7 (3.1)                 40/16 (2.5)                0.55
  BMI, kg/m^2^               17.23 ± 2.97               17.63 ± 2.71               0.55
  Allergic rhinitis, N (%)   12 (46.2)                  39 (69.6)                  0.006
  GER, N (%)                 1 (3.4)                    5 (8.9)                    0.174
  Asthma management, N (%)                                                         
   Never treated             8 (27.6)                   18 (32.1)                  0.332
  Occasionally treated       13 (44.8)                  21 (37.5)                  0.256
  Correctly treated          8 (27.6)                   17 (30.4)                  0.395
  Asthma severity, N (%)                                                           
  Intermittent               5 (17.2)                   11 (19.6)                  0.394
  Mild                       17 (58.6)                  30 (50.8)                  0.328
  Moderate                   7 (24.2)                   15 (30.4)                  0.395
  Asthma control, N (%)                                                            
  Controlled                 6 (20.7)                   10 (17.9)                  0.375
  Partial controlled         9 (31.0)                   16 (28.6)                  0.406
  Uncontrolled               14 (48.3)                  30 (53.5)                  0.321
  ACT, score                 19.9 ± 4.1                 20.5 ± 3.6                 0.572
  Eosinophil, %              7.2 ± 6.2                  5.9 ± 4.2                  0.24
  FEV~1~, %                  94.8 ± 15.2                86.5 ± 15.6                0.022
  Exhaled NO, ppb                                                                  
   Bronchial FENO            14.3 ± 11.9                21.0 ± 12.9                0.034
   Nasal FENO                1489 ± 833                 1501 ± 954                 0.954
   C~A~NO                    3.2 ± 2.1                  6.5 ± 7.3                  0.028
  Polygraphy                                                                       
   AHI (min, max)            --                         3.4 ± 3.5 (0--13)          --
   SpO~2~                    92 ± 2                     92 ± 4                     0.791
   Nadir SpO~2~, %           86 ± 8                     82 ± 7                     0.405
   ODI,/h                    1.6 ± 2.2                  2.3 ± 2.4                  0.315

**Abbreviations:** ACT, asthma control test; AHI, apnea--hypopnea index; BMI, body mass index; CANO, alveolar concentration of nitric oxide; FENO, fractional exhaled nitric oxide; FEV~1~, forced expiratory flow in 1 second; FVC, forced vital capacity; GER, gastroesophageal reflux; max, maximum; min, minimum; NO, nitric oxide; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; PEF, peak expiratory flow.

###### 

Characteristics of nocturnal and day-time symptoms

  Characteristics             Asthma-OSA (−), N = 29   Asthma-OSA (+), N = 56   *P*
  --------------------------- ------------------------ ------------------------ ---------
  Nocturnal symptoms, N (%)                                                     
   Snoring                    5 (17.2)                 27 (48.2)                0.002
   Difficulty sleeping        5 (17.2)                 11 (19.6)                0.397
   Dyspnea during sleep       7 (24.1)                 32 (57.1)                0.002
   Witness of apnea           0 (0)                    1 (1.7)                  0.234
   Sleep disturbance          8 (27.5)                 40 (71.4)                \<0.001
   Frequently awake           12 (41.3)                16 (28.5)                0.116
   Nocturnal sweats           9 (31.0)                 32 (55.1)                0.011
   Enuresis                   10 (34.4)                6 (10.7)                 0.003
  Daytime symptoms, N (%)                                                       
   Abnormal behavior          9 (31.0)                 13 (23.2)                0.217
   Irritability               8 (27.5)                 21 (37.5)                0.180
   Reduced awareness          0 (0)                    2 (3.5)                  0.151
   Daytime sleepiness         11 (37.9)                9 (16.0)                 0.012
   Doze                       0 (0)                    13 (23.2)                0.002

**Abbreviation:** OSA, obstructive sleep apnea.

###### 

Measure of odds ratio for OSA in the study subjects with asthma

  Parameters                Odds ratio   CI 95% Odds ratio   *P*
  ------------------------- ------------ ------------------- -------
  Allergic rhinitis         6.8          2.2--20.7           0.001
  Snoring                   4.9          1.8--13.3           0.002
  Disturbed sleep           2.0          0.8--5.4            0.156
  Dyspnea during sleep      4.2          1.5--11.4           0.005
  Nocturnal sweats          1.1          0.4--2.7            0.862
  FEV~1~\<80%               3.0          0.9--9.8            0.067
  Bronchial FENO \>20 ppb   0.9          0.4--2.3            0.840
  C~A~NO \>5 ppb            0.9          0.4--2.3            0.862

**Abbreviations:** C~A~NO, alveolar concentration of nitric oxide; FENO, fractional exhaled nitric oxide; FEV~1~, forced expiratory volume in 1 s; NO, nitric oxide; OSA, obstructive sleep apnea; ppb, part per billion.
